Juan A. Sánchez‐Arias

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

Edurne San José‐Eneriz, Xabier Agirre, Obdulia Rabal et al. · Nature Communications · 2017 · 161 citations · Full text

Hematological Malignancy, Reversible Chemical Probes, Epigenetic Drugs +15

Amylin as a potential link between type 2 diabetes and alzheimer disease

Iván Martínez-Valbuena, Rafael Valenti‐Azcarate, Irene Amat‐Villegas et al. · Annals of Neurology · 2019 · 105 citations

A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice

Mar Cuadrado‐Tejedor, Carolina García, Juan A. Sánchez‐Arias et al. · Neuropsychopharmacology · 2016 · 103 citations · Full text

Dual Inhibitor, Synaptic Transmission, Molecular Biology +17

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease

Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor et al. · Journal of Medicinal Chemistry · 2016 · 85 citations · Full text

Hdac Inhibitors, Drug Target, Neurochemical Biomarkers +17

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor et al. · European Journal of Medicinal Chemistry · 2018 · 67 citations · Full text

Dual Phosphodiesterase 5, Medicinal Chemistry, Neurodegenerative Diseases +12